Medicinal Products

ATROPINE SULFATE AGUETTANT 01 mg / mL

Generic Drug Therapeutic Class: Diagnostic Products or Other Therapeutic Products
active ingredients: Atropine, Atropine, Atropine
laboratory: Aguettant

Injectable solution
in pre-filled syringe box of 10 pre-filled syringes of 5 ml
All forms

Indication

· Preoperative treatment: Prevention of vaginal reactions (arrhythmia, bradycardia) associated with tracheal intubation and surgical manipulation.

· Cardiopulmonary resuscitation: treatment of sinus bradycardias and atrioventricular blocks.

· In combination with neostigmine: limitation of the muscarinic effects of neostigmine used after surgery for the neutralization of nondepolarizing muscle relaxants.

· Specific antidote in case of overdose of anticholinesterase, acute intoxication by organophosphorus (insecticides, nerve gas used as a chemical weapon, carbamates) or muscarinic mushrooms.

Dosage ATROPINE SULFATE AGUETTANT 01 mg / mL solution for injection in pre-filled syringe box of 10 pre-filled syringes of 5 ml

· Preoperative treatment: Prevention of vaginal reactions (arrhythmia, bradycardia) associated with tracheal intubation and surgical manipulation.

· Cardiopulmonary resuscitation: treatment of sinus bradycardias and atrioventricular blocks.

· In combination with neostigmine: limitation of the muscarinic effects of neostigmine used after surgery for the neutralization of nondepolarizing muscle relaxants.

· Specific antidote in case of overdose of anticholinesterase, acute intoxication by organophosphorus (insecticides, nerve gas used as a chemical weapon, carbamates) or muscarinic mushrooms.

Against indications

· Hypersensitivity to the active substance or to any of the excipients,

· Angle closure glaucoma

· Risk of urinary retention due to prostate or urethral disease,

· Myasthenia gravis unless administered in combination with anticholinesterase,

· Breastfeeding (see section on Pregnancy and lactation )

· Achalasia of the esophagus.

Adverse effects Atropine Sulfate Aguettant

The most commonly reported adverse events are due to the effect of atropine on muscarinic receptors and high dose on nicotinic receptors. These effects are dose-related and are usually reversible upon discontinuation of therapy.

Immune system disorders:

Anaphylaxis.

Nervous system disorders:

Nervousness, mental confusion, especially in the elderly. At higher doses, hallucinations, agitation, delirium.

Eye disorders:

Dilation of pupils accompanied by loss of accommodation and photophobia, decrease of lacrimal secretion, increase of intraocular pressure.

Heart conditions:

Tachycardia, palpitations, arrhythmia.

Vascular disorders:

Redness.

Respiratory, thoracic and mediastinal disorders:

Thickening of bronchial secretions.

Gastrointestinal disorders:

Dry mouth, nausea, vomiting, constipation.

Renal and urinary disorders:

Urinary retention.

Skin and subcutaneous tissue disorders:

Dryness of the skin

General disorders:

Thirst.

Reporting of suspected adverse reactions

The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Healthcare professionals declare any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (Ansm) and the network of Regional Pharmacovigilance Centers - Website: www.ansm.sante.fr

Popular Posts

Category Medicinal Products, Next Article